Portugal, SpainPortugal

Biotecnol and Digna Biotech co-develop hepato-protective drug


Oeiras/Navarra – Portuguese antibody and genomics specialist Biotecnol SA and the Spanish university spin-off Digna Biotech will develop a process for manufacturing cardiotrophin-1 (CT-1) for the treatment of ischemic-reperfusion injury after liver transplantation.
Under the terms of the cross licence agreement, announced at the beginning of June, Biotecnol will set up a production process for CT-1, the member of the interleukin-6 cytokine family, with an option to progress to GMP manufacture, and onto control and release of the finished product. Digna Biotech obtained EU Orphan Drug Status (EU/3/06/396) for the use of CT1 in organ transplantation, including liver transplants and will apply to the FDA for Orphan Drug Status in the USA, initially for use of CT-1 in hepatic transplantation.
Digna Biotech will provide financial support and will gain access to Biotecnol’s proprietary production platforms and process development know-how, by paying agreed milestones. Digna Biotech has further options to subcontract future work to Biotecnol, which includes the manufacture of the finished product for a renewable five-year period, beginning with the release of the first successful finished product batch for clinical trials, for which Biotecnol will receive agreed milestone payments.
“This is probably the first sizeable deal in the biopharmaceutical sector between a Portuguese and a Spanish company”, said José Honorato Ferreira, Board Member of Biotecnol and member of Fundação Luso-Espanhola, an organisation dedicated to promote the networking and cooperation between the two countries.
“Digna Biotech has impressive expertise and in-depth knowledge in the field of liver diseases”, said Pedro de Noronha Pissarra, Chief Executive Officer of Biotecnol.
Sp1 has demonstrated hepato-protective effects in lab mice (Hepatology. 2007 Mar;45(3):639-48).



Lisbon – Genetically modified organisms (GMOs) are gaining ground in southwestern Europe. According to the European Association for Bioindustries (EuropaBio), Portuguese farmers planted nearly 60% more genetically modified maize...



Lisbon – In the southwest of Europe, GMOs are gaining ground. According to the European Association for BioIndustries EuropaBio, Portuguese farmers have grown nearly 60% more genetically modified (GM) maize this year compared to...



Lisbon – According to a report published by business intelligence provider Espicom, the future for biopharma on the westernmost tip of Europe looks anything but sunny. Its analysts predict that by 2016, the pharmaceuticals market...



Lisbon – Portugal’s “Fundação para a Ciência e Tecnologia” (FCT) is to channel funding into collaborations between Portuguese and Indian life science companies and research within the networking pilot programme “New Indigo”...



Coimbra/San Francisco/Munster – Portuguese and US researchers have discovered a new factor that determines whether an embryonic stem cell (ESC) will remain pluripotent or not. After the team under Miguel and Joao Ramalho-Santos...



Madrid –The Spanish Ministry of Health is investing in future biotech treatments. In July, it signed a EUR60m contract over a recombinantly manufactured flu vaccine developed by Rockville-based Novavax. In Phase II trials, the...


Lisbon/New York - A Portuguese-US research team has discovered a new molecular mechanism that enables gamma herpes viruses to chronically infect patients. Gamma herpes viruses infect white blood cells (B- or T-lymphocytes)...



Lisbon – Portugal’s Bial SA has granted American company Sepracor the exclusive rights to develop and commercialise eslicarbazepine in the United States and Canada. Bial will receive US$57m up front.

Displaying results 1 to 10 out of 37

1-10 Next >

© 2007-2016 BIOCOM



Current issue

All issues

Product of the week


Stock list

All quotes


  • NEWRON (CH)22.65 CHF9.69%
  • VERNALIS (UK)45.00 GBP4.65%
  • KARO BIO (S)40.00 SEK4.44%


  • PROTHENA PLC (IE)50.02 USD-7.70%
  • BIONOR PHARMA (N)0.44 NOK-6.38%


  • DIAMYD MEDICAL -B- (S)7.25 SEK68.6%
  • KARO BIO (S)40.00 SEK28.6%
  • MOLMED (I)0.42 EUR27.3%


  • BIONOR PHARMA (N)0.44 NOK-27.9%
  • NOVOZYMES (DK)284.40 DKK-14.3%
  • RENEURON (UK)2.75 GBP-12.4%


  • NICOX (F)10.26 EUR442.9%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%
  • GENMAB (DK)1126.00 DKK100.9%


  • BB BIOTECH (D)46.74 EUR-81.5%
  • EVOCUTIS (UK)0.04 GBP-80.0%
  • CIRCASSIA LIMITED (L)94.70 GBP-70.9%

No liability assumed, Date: 25.08.2016


All Events